Evaluation of immunological status in tumor-bearing dogs

Veterinary Immunology and Immunopathology

Volumn 132, Issue 2-4, 2009, Pages 85-90

  Itoh, Hiroshi ^a   Horiuchi, Yutaka ^b,c   Nagasaki, Teppei ^d   Sakonju, Iwao ^e   Kakuta, Tomoko ^e   Fukushima, Ushio ^f   Uchide, Tsuyoshi ^e   Yamashita, Mariko ^b   Kuwabara, Masato ^c   Yusa, Sei ichi ^g   Takase, Katsuaki ^e  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b Japan Animal Referral Medical Center   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d Zentsuji Animal Hospital   (Japan)

^e KITASATO UNIVERSITY   (Japan)

^f Kamakurayama Animal Hospital   (Japan)

^g Tella Inc   (Japan)

Author keywords

Lymphocyte; Phenotype; Tumor bearing dogs

Indexed keywords

INTERLEUKIN 6; OROSOMUCOID; TRANSFORMING GROWTH FACTOR BETA;

ADVANCED CANCER; ANIMAL CELL; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; HUMORAL IMMUNITY; IMMUNE STATUS; INFLAMMATORY CELL; LEUKOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; NEUTROPHIL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR IMMUNITY;

AGING; ANIMALS; CASE-CONTROL STUDIES; DOG DISEASES; DOGS; FEMALE; IMMUNE TOLERANCE; INTERLEUKIN-6; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; NEOPLASM STAGING; NEOPLASMS; OROSOMUCOID; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA;

CANIS FAMILIARIS;

EID: 70449517479     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.04.020     Document Type: Article

References (35)

1. Berghella A.M., Pellegrini P., Del Beato T., Marini M., Tomei E., Adorno D., and Casciani C.U. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immnunol. Immunother. 45 (1998) 241-249
2. Blay J.Y., Burdin N., Rousset F., Lenoir G., Biron P., Philip T., Banchereau J., and Favrot M.C. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82 (1993) 2169-2174
3. Blay J.Y., Negrier S., Combaret V., Attali S., Goillot E., Merrouche Y., Mercatello A., Ravault A., Tourani J.M., and Moskovtchenko J.F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Tumor Res. 52 (1992) 3317-3322
4. Brabletz T., Pfeuffer I., Schorr E., Siebelt F., Wirth T., and Serfling E. Transforming growth factor β and cyclosporine A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol. Cell Biol. 13 (1993) 1155-1162
5. Bronson R.T. Variation in age at death of different sexes and breeds. Am. J. Vet. Res. 43 (1982) 2057-2059
6. Broder S., and Waldmann T.A. The suppressor cell network in tumor (first of two parts). N. Engl. J. Med. 299 (1978) 1281-1284
7. Byrne K.M., Kim H.W., Chew B.P., Reinhart G.A., and Hayek M.G. A standardized gating technique for the generation of flow cytometry data for normal canine and normal feline blood lymphocytes. Vet. Immunol. Immunopathol. 73 (2000) 167-182
8. Duthie S., Eckersall P.D., Addie D., Lawrence C., and Jarrett E.O. Value of α1-acid glycoprotein in the diagnosis of feline infectious peritonitis. Vet. Rec. 141 (1997) 299-303
9. Fujimoto S., Greene M.I., and Sehon A.H. Regulation of the immune response to tumor antigens. The nature of immunosuppressor cells in tumor-bearing hosts. J. Immunol. 116 (1976) 791-799
10. Fujiwara H., and Hamaoka T. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol. Res. 14 (1995) 271-291
11. Itoh H., Tamura K., Motoi Y., Takase K., and Nakamura T. Serum α1-acidic glycoprotein in cattle with inflammatory disease and that after operation. Jpn. J. Vet. Sci. 52 (1990) 1293-1296
12. Itoh H., Kakuta T., Kudo T., Sakonju I., Hohdatsu T., Ebina T., and Takase K. Bulk cultures of canine peripheral blood lymphocytes with solid phase anti-CD3 antibody and recombinant interleukin-2 for use in immunotherapy. J. Vet. Med. Sci. 65 (2003) 1329-1333
13. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S., Alvarez-Mon M., Derynck R., Sporn M.B., and Fauci A.S. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163 (1986) 1037-1050
14. Kishi A., Ohmori M., Tomita S., Uno K., and Tanigawa M. Phenotypic and functional analyses of natural killer cells: impaired NK activity partly due to the CD56+ cell dysfunction in cancer patients. Int. J. Immunother. 15 (1999) 1-12
15. Kirchner H., Chused T.M., Herberman R.B., Holden H.T., and Lavrin D.H. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J. Exp. Med. 139 (1974) 1473-1487
16. + T cell function. Jpn. J. Tumor Res. 84 (1993) 315-325
17. Maruo S., Oh-hora M., Ahn H.J., Ono S., Wysocka M., Kaneko Y., Yagita H., Okumura K., Kikutani H., Kishimoto T., Kobayashi M., Hamaoka T., Trinchieri G., and Fujiwara H. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interaction. J. Immunol. 158 (1997) 120-126
18. Mossman T.R., and Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7 (1989) 145-173
19. Nakanishi A., Aimi K., Ejima H., and Kurosawa K. Measurement of blastogenesis of canine peripheral blood lymphocytes against PHA by glucose consumption test. Jpn. J. Vet. Sci. 48 (1986) 53-60
20. Oka M., Hirose K., Iizuka N., Aoyagi K., Yamamoto K., Abe T., Hazama S., and Suzuki T. Cytokine mRNA expression patterns in human esophageal cancer cell lines. J. Interferon Cytokine Res. 15 (1995) 1005-1009
21. 2 levels and lymphocyte subsets in portal venous drainage of colorectal cancers. Am. J. Surg. 167 (1994) 264-267
22. Oka M., Yamamoto K., Takahashi M., Hakozaki M., Abe T., Iizuka N., Hazama S., Hirazawa K., Hayashi H., Tangoku A., Hirose K., Ishihara T., and Suzuki T. Relationship between serum levels of interleukin 6, various disease parameters, and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 56 (1996) 2776-2780
23. Pace J.L., Russell S.W., Torres B.A., Johnson H.M., and Gray P.W. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J. Immunol. 130 (1983) 2011-2013
24. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., and Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73 (1994) 1882-1888
25. Paul W.E., and Seder R.A. Lymphocyte responses and cytokines. Cell 76 (1994) 241-251
26. Svedersky L.P., Benton C.V., Berger W.H., Rinderknecht E., Harkins R.N., and Palladino M.A. Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor. J. Exp. Med. 159 (1984) 812-827
27. Selting K.A., Ogilvie G.K., Lana S.E., Fettman M.J., Mitchener K.L., Hansen R.A., Richardson K.L., Walton J.A., and Scherk M.A. Serum alpha 1-acid glycoprotein concentrations in healthy and tumor-bearing cats. J. Vet. Intern. Med. 14 (2000) 503-506
28. Tamura K., Shibata Y., Matsuda Y., and Ishida N. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res. 41 (1981) 3244-3252
29. + T cells in the tumor bearing state. J. Leukoc. Biol. 47 (1990) 149-157
30. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.F., Shimizu J., Fujiwara H., and Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J. Immnol. 146 (1991) 1077-1082
31. Takiuchi H., Tada T., Li X.F., Ogata M., Ikeda T., Fujimoto S., Fujiwara H., and Hamaoka T. Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form. Cancer Res. 52 (1992) 5641-5646
32. Treves A.J., Carnaud C., Trainin N., Feldman M., and Cohen I.R. Enhancing T lymphocytes from tumor-bearing mice suppress host resistance to a syngeneic tumor. Eur. J. Immunol. 4 (1974) 722-727
33. Utsumi K., Tkai Y., Tada T., Ohzeki S., Fujiwara H., and Hamaoka T. Enhanced production of IL 6 in tumor bearing mice and determination of cells responsible for its augmented production. J. Immunol. 145 (1990) 397-403
34. Yamamoto N., Zou J.P., Li X.F., Takenaka H., Noda S., Fujii T., Ono S., Kobayashi Y., Mukaida N., Matsushima K., Fujiwara H., and Hamaoka T. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state. J. Immunol. 154 (1995) 2281-2290
35. + T cell activity. J. Immunol. 148 (1992) 648-655